Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3933)

THE GROUP'S PRODUCT SEMAGLUTIDE INJECTION MARKETING REGISTRATION APPLICATION BEEN ACCEPTED

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the marketing registration application for the weight management indication of Semaglutide Injection, submitted by Zhuhai United Bio-Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, has been accepted by China National Medical Products Administration, with the application acceptance numbers CXSS2600179, CXSS2600180, CXSS2600181, CXSS2600182 and CXSS2600183.

Semaglutide Injection is a long-acting recombinant human glucagon-like peptide-1 (GLP-1) analogue, primarily indicated for glycemic control in patients with type 2 diabetes, long-term weight management in patients with obesity or overweight, reduction of major adverse cardiovascular event (MACE) risk in patients with obesity or overweight and treatment of patients with MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis. Administered by subcutaneous injection once a week, it achieves significant weight loss through multiple mechanisms, including appetite suppression, delayed gastric emptying and regulation of energy metabolism, and improvement of liver histology, while also delivering comprehensive benefits such as reducing the risk of cardiovascular events and treating steatohepatitis with liver fibrosis, offering an efficient, convenient, and comprehensive long-term weight management solution for patients with obesity or overweight.

Previously, in January 2025, the Company submitted a marketing registration application for the diabetes indication of Semaglutide Injection, which has been accepted for review. This new marketing application for the weight management indication further broadens the product's indication portfolio and is expected to bring clinical benefits to a wider patient population.

Focusing on the GLP-1 target, the Company has established a differentiated product pipeline integrating innovative drugs and biosimilars, thereby enhancing its competitiveness in the biopharmaceutical sector. Looking ahead, the Company will continue to invest in the research and development of new products, which is expected to create greater values for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 4 November 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.